This paper is in the following e-collection/theme issue:

Corrigenda and Addenda (1)

Published on in Vol 2, No 1 (2018): Jan-Jun

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/10149, first published .
Correction: Assessing the Use of Wrist-Worn Devices in Patients with Heart Failure: Feasibility Study

Correction: Assessing the Use of Wrist-Worn Devices in Patients with Heart Failure: Feasibility Study

Correction: Assessing the Use of Wrist-Worn Devices in Patients with Heart Failure: Feasibility Study

Authors of this article:

Yasbanoo Moayedi1 Author Orcid Image ;   Raghad Abdulmajeed2 Author Orcid Image ;   Juan G. Duero Posada1 Author Orcid Image ;   Farid Foroutan1 Author Orcid Image ;   Ana Carolina Alba1 Author Orcid Image ;   Joseph A. Cafazzo2 Author Orcid Image ;   Heather J. Ross1 Author Orcid Image
Article Authors Cited by (1) Tweetations (2) Metrics

    Corrigenda and Addenda

    1Ted Rogers Centre of Excellence in Heart Function, University Health Network, Toronto, ON, Canada

    2Centre for Global eHealth Innovation, Techna Institute, University Health Network, Toronto, ON, Canada

    Corresponding Author:

    Heather Joan Ross, MD, MHSc

    Ted Rogers Centre of Excellence in Heart Function

    University Health Network

    Toronto General Hospital

    190 Elizabeth St

    Toronto, ON, M5G 2C4

    Canada

    Phone: 1 416 340 3482

    Email: heather.ross@uhn.ca



    The authors of the paper “Assessing the Use of Wrist-Worn Devices in Patients with Heart Failure: Feasibility Study” (Cardio JMIR 2017;1 (2): July-Dec) made a mistake by including a patient who had heart failure with preserved ejection fraction. This finding was just brought to the authors’ attention. They apologize for this oversight but have taken all measures to ensure that correct data is displayed in the article.

    In the Introduction section, the following has been removed from the end of the final sentence:

    ...with reduced ejection fraction (HFrEF; ejection fraction <40%) anda NYHA Class II and III, as measured by daily steps by these two devices.

    In the Methods section, the mention of “HFrEF” has been changed to “HF”. “HFrEF” has also been removed from the paper's Abbreviations list.

    In the Results section, the second and third sentences of the paragraph beginning with “Table 1...” has been changed to the following:

    Patients were predominantly male (5/8, 63%), with an average age of 58 years and ischemic cardiomyopathy (5/8, 63%). All patients were on guideline-directed medical therapy including a betablocker and either an angiotensin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB) when indicated.

    Specifically, the text which was previously “(6/8, 75%)” now reads “(5/8, 63%)”. The average age was “57” and is now “58”, and the phrase “when indicated” has been added to the end of the latter sentence.

    The caption for Table 1 has been shortened from “Demographics and baseline data of patients included in phase 2 of the study” to “Demographics and baseline data”. In Table 1 itself, data for Patient 7 has been changed under the following columns:

    Age (years): “51” changed to “58”
    Gender: “Male” changed to “Female”
    LVEFa, %: “35” changed to “60”
    Etiology of HFb: “Ischemic” changed to “Familial”
    Medicationsd, Betablocker: “Carvedilol 12.5 mg” changed to “None”
    Medicationsd, Other: “Ramipril 10 mg” changed to “None”

    The updated version of Table 1 is available below.

    The corrected article will appear in the online version of the paper on the JMIR website on May 4, 2018, together with the publication of this correction notice. Because this was made after submission to PubMed, Pubmed Central, and other full-text repositories, the corrected article also has been re-submitted to those repositories.

    Table 1. Demographics and baseline data.

    Number
    Age (years)
    Gender    		LVEFa, %Etiology of HFbNYHAc classMedicationsd
    BetablockerAmiodaroneOther
    167Male40Ischemic3Bisoprolol 2.5 mgNoneCandesartan 8 mg
    268Male18Ischemic2Bisoprolol 10 mg200Irbesartan 300 mg
    363Male25Ischemic3Bisoprolol 10 mgNonePerindopril 8 mg
    461Female27Non-ischemic2Bisoprolol 10 mgNonePerindopril 4 mg
    552Male25Ischemic2Bisoprolol 10 mgNonePerindopril 8 mg
    657Female27Non-ischemic3Carvedilol 25 mgNoneRamipril 2.5 mg
    758Female60Familial2NoneNoneNone
    835Male33Hypertrophic3Carvedilol 50 mgNoneRamipril 10 mg

    aLVEF: left ventricular ejection fraction.

    bHF: heart failure.

    cNYHA: New York Heart Association.

    dDrug doses are total daily dose.

    Edited by G Eysenbach; This is a non–peer-reviewed article. submitted 15.02.18; accepted 04.04.18; published 04.05.18.

    Copyright

    ©Yasbanoo Moayedi, Raghad Abdulmajeed, Juan G. Duero Posada, Farid Foroutan, Ana Carolina Alba, Joseph A. Cafazzo, Heather J. Ross. Originally published in JMIR Cardio (http://cardio.jmir.org), 04.05.2018.

    This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Cardio, is properly cited. The complete bibliographic information, a link to the original publication on http://cardio.jmir.org, as well as this copyright and license information must be included.